Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 1998

View Archived Issues

ZymeTx signs agreement for potential HIV antiviral technology

Enzo Biochem initiates phase I clinical trials of HIV-1 treatment

Generex submits IND for Oralin in Canada

New clinical trial of G-3139 in prostate cancer gets under way at U.S. center

NeXstar initiates third phase II MiKasome trial

Increased sexual activity in Muse-treated men does not mean increased risk of CV side effects

Ribi acquires new adjuvant technology from U of Nebraska

Promising phase II results reported for BTI-322 in GVHD

StressGen establishes multiinstitutional collaboration for stress protein-modulating drugs

Arylureas and arylmethylcarbamoyl derivatives as ACAT inhibitors

Antimetastatic antibiotic isolated from Penicillium at Takara Shuzo

Potent, broad-spectrum antibacterial compounds developed at Daiichi

Yoshitomi prepares agents for hyperuricemia and gout

Antifungal series emerges from R&D at Pola

Profile of the second-generation alkylphosphocholine perifosine

RiboGene receives additional funding in the area of antifungals

Altana offer to license Solarase accepted by Hyal

Joint development agreement for Hyanalgese-D announced by Hyal

Xoma now owns or has exclusive rights to all BPI-related patents

Restless legs syndrome: description and treatment options

Hypnotic effects of the benzodiazepine receptor ligand SX-3228 in rats

Calcium channel blockers reduce craving for alcohol

SIB-1553A goes head-to-head with established cognition-enhancing drugs

HMR arthritis Rx up for FDA committee review

EEG analysis reveals the atypical antipsychotic profile of OPC-14597

New indication explored for established anticonvulsant